Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | NPFFR1 | Q9GZQ6 | 7/20 | 0.66 |
| ▸ | NPFFR2 | Q9Y5X5 | 7/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654357 | 0.92 | ALDH1A1 (0.62) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL3939085 | 0.91 | CYP2D6 (0.65) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL5556286 | 0.91 | ALDH1A1 (0.61) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL16876726 | 0.91 | ALDH1A1 (0.61) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL18358788 | 0.91 | CYP2D6 (0.61) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL2985624 | 0.89 | NPFFR1 (0.62) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL7707050 | 0.88 | ALDH1A1 (0.61) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL20187124 | 0.88 | ALDH1A1 (0.58) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL8893210 | 0.88 | ALDH1A1 (0.61) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 | |
| SCHEMBL20187134 | 0.88 | CYP2D6 (0.58) | CYP2D6ALDH1A1NPFFR1NPFFR2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102442937-A | Method for preparing 1-benzyl-4-anilinopiperidine-4-carboxylic acid | SICHUAN SAINANDE TECHNOLOGY CO LTD | 2012-05-09 | — | — | CN | claimed |
| CN-113480536-B | Spiropiperidone derivatives | 中国人民解放军海军军医大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-117069720-A | 5-HT 2A Receptor agonist, preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-113480536-A | Spirocyclic piperidone derivatives | 中国人民解放军海军军医大学 | 2021-10-08 | — | — | CN | disclosed |
| CN-107849044-B | Triaza-spirodecanones as DDR1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-4208418-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-06-17 | — | — | US | disclosed |
| US-4198411-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-15 | — | — | US | disclosed |
| US-4197303-A | ANTIARRHYTHMIA AGENTS, ALKOXYCARBONYL ON 4-POSITION OF PIPERIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4197304-A | ANTIARRHYTHMIA AGENTS, N-PYRIDINYL-N-(4-ALKYLPIPERIDINYL)THIENYLACETAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4196210-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-01 | — | — | US | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-4157393-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-06-05 | — | — | US | disclosed |
| US-4151286-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-04-24 | — | — | US | disclosed |
| US-4126689-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | CYP2D6 3278/4885ALDH1A1 1320/4885NPFFR1 3034/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | CYP2D6 3278/4885ALDH1A1 1320/4885NPFFR1 3034/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | CYP2D6 3278/4885ALDH1A1 1320/4885NPFFR1 3034/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | CYP2D6 3278/4885ALDH1A1 1320/4885NPFFR1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.